ClotCare: Blood Clots, Stroke, Heart Attack
Friday, October 24, 2014
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Editorial Board

Victor F. Tapson, MD

Dr. Victor Tapson is Professor of Medicine at the Division of Pulmonary and Critical Care Medicine at Duke University Medical Center, in Durham, North Carolina, USA. He serves as Director of the Duke Pulmonary Vascular Disease Center. He spent 10 years as Medical Director of the Duke University Lung Transplant Program. His internship and residency were at Duke, and he became a Fellow in Pulmonary Medicine in 1986 at Boston University Medical Center and Boston City Hospital in Boston, MA.

Dr. Tapson has received several awards for his work including the American College of Chest Physicians (ACCP) Ciba-Geigy Fellowship Award, Alfred Soffer Research Award and Young Investigators Award. He is Chairman of the American Thoracic Society Consensus Statement for the Diagnostic Approach to Acute Venous Thromboembolism (VTE) as well as for their Therapeutic Approach to Acute VTE statement. He serves as a member of the ACCP Consensus Statement on Antithrombotic Therapy. He is also an active member of several societies, including the Pulmonary Hypertension Association Scientific Leadership Committee, the Pulmonary Circulation Assembly of the American Thoracic Society, and the International Society of Thrombosis and Haemostasis.

Dr. Tapson has authored and co-authored over 140 papers in peer-reviewed journals and more than 10 book chapters. He has edited two issues of Clinics in Chest Medicine reviewing VTE and has chaired more than 50 symposia on this topic at national and international meetings and enjoys giving lectures on this subject to medical students, nurses, interns and residents, and other physicians and health care personnel. He has lectured at the Royal College of Physicians in Edinborough and at both the American College of Chest Physicians and the American Thoracic Society every year for the past decade.

Venous Thromboembolism

Dr. Tapson’s early research work involved pharmacomechanical thrombosis of massive pulmonary embolism, which was initiated in the animal lab and extended to the clinical arena. He studied the role of MRI in the diagnosis of deep vein thrombosis. He currently serves on the steering committee and executive committee for the NIH-sponsored PIOPED II (spiral CT scan) clinical trial. He is the U.S. principal investigator for an international VTE prevention trial (EXCLAIM) which is now underway. He is the co-principal investigator of two venous thromboembolism registries, one involving 5,000 patients in the U.S. (DVT-FREE), and one international registry involving venous thrombosis prevention in medically ill patients (IMPROVE). He served as the PI for the NABOR study, a 4000 patient anticoagulation benchmarking study recently conducted and presented at ACCP in 2003. Finally, he serves on the steering committee for the CATCH (heparin-induced thrombocytopenia) registry and for the prospective, randomized, EXPEDITE trial evaluating the use of ximelegatran for acute venous thromboembolism.

He has been a member of the American College of Chest Physicians Consensus on Antithrombotic Therapy for the past five years as well as serving on two Opinion Statements for the ACCP involving VTE. He chaired the American Thoracic Society’s Clinical Practice Guideline on the Diagnostic Approach to Venous Thromboembolism in 1999, and currently serves as the chair for a consensus statement on the management of pulmonary embolism for the ATS. He has edited two issues of Clinics in Chest Medicine devoted to VTE, and recently edited an issue of Seminars in Respiratory and Critical Care Medicine, also on pulmonary embolism. He has chaired dozens of national and international symposia on this topic.

Pulmonary Hypertension

His involvement in major multicenter clinical trials leading to FDA-approval for continuous intravenous epoprostenol, subcutaneous treprostinil, bosentan, beraprost, sitaxsentan, and sildenafil has been rewarding. Additional projects include collaborating with basic scientists at Duke to utilize ethyl nitrite for long-term PH treatment. For the past several years, he has been involved with developing both a PH and a VTE database and these are nearing completion. He continues to serve on the Scientific Leadership Committee for the Pulmonary Hypertension Association and has served as the editor for Pathlight, the periodical published by this organization. He is also serving as the first editor for Advances in Pulmonary Hypertension, a journal dedicated to this disease. In the future, he will continue to be involved with clinical trials in VTE and PH. He plans increased collaboration with basic science laboratories (vascular biology and anticoagulation). He will serve on the steering committee of a proposed NIH study involving anticoagulation and pulmonary hypertension.

Dr. Tapson is on the editorial board of Seminars in Respiratory and Critical Care Medicine and has authored or coauthored over 140 articles, publishing in such journals as the New England Journal of Medicine, Annals of Internal Medicine, Chest, Lancet, and Circulation.

Dr. Tapson receives research support from Aventis, Astra-Zeneca, Actelion, United Therapeutics, Encysive, Cotherix, and Berlex. He is a consultant for Aventis and Astra-Zeneca and serves on the Speaker’s bureau for Aventis and Astra-Zeneca.

Editorial Board Members

Return to Editorial Board main page
Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Friday, October 24, 2014